Cargando…
THER-01. Targeted therapy and intracranial metastatic disease: a population-based retrospective cohort study
BACKGROUND: Targeted therapies have been hypothesized to prolong survival in the management of patients with intracranial metastatic disease (IMD), but, paradoxically, to increase IMD incidence by improving systemic disease control and prolonging survival from the primary tumor. The real-world benef...
Autores principales: | Erickson, Anders, Habbous, Steven, Wright, Frances, Lofters, Aisha, Jerzak, Katarzyna, Das, Sunit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351316/ http://dx.doi.org/10.1093/noajnl/vdab071.048 |
Ejemplares similares
-
SYST-03 INCIDENCE AND SURVIVAL OF PATIENTS WITH INTRACRANIAL METASTATIC DISEASE AND ERBB2-POSITIVE GASTROINTESTINAL CANCERS: A RETROSPECTIVE COHORT STUDY
por: Sherman, Madison, et al.
Publicado: (2022) -
Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders Wilder, et al.
Publicado: (2021) -
04. ASSESSMENT OF EFFICACY AND SAFETY OF OSIMERTINIB FOR PATIENTS WITH INTRACRANIAL METASTATIC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Erickson, Anders, et al.
Publicado: (2020) -
HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders W, et al.
Publicado: (2020) -
34. TARGETED THERAPY FOR HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Erickson, Anders, et al.
Publicado: (2020)